Research programme: hydroxysteroid dehydrogenase inhibitors - Bioenvision
Latest Information Update: 16 Mar 2007
At a glance
- Originator Unknown
- Mechanism of Action Hydroxysteroid dehydrogenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 28 Oct 2003 Preclinical trials in Prostate cancer in United Kingdom (unspecified route)